Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Depreciation & Amortization (CF): 2023-2025

Historic Depreciation & Amortization (CF) for Artiva Biotherapeutics (ARTV) over the last 3 years, with Sep 2025 value amounting to $662,000.

  • Artiva Biotherapeutics' Depreciation & Amortization (CF) rose 5.58% to $662,000 in Q3 2025 from the same period last year, while for Sep 2025 it was $2.5 million, marking a year-over-year increase of 5.56%. This contributed to the annual value of $2.4 million for FY2024, which is 7.28% up from last year.
  • Latest data reveals that Artiva Biotherapeutics reported Depreciation & Amortization (CF) of $662,000 as of Q3 2025, which was up 3.28% from $641,000 recorded in Q2 2025.
  • In the past 5 years, Artiva Biotherapeutics' Depreciation & Amortization (CF) ranged from a high of $662,000 in Q3 2025 and a low of $556,000 during Q3 2023.
  • For the 3-year period, Artiva Biotherapeutics' Depreciation & Amortization (CF) averaged around $611,200, with its median value being $608,500 (2024).
  • Data for Artiva Biotherapeutics' Depreciation & Amortization (CF) shows a peak YoY rose of 12.77% (in 2024) over the last 5 years.
  • Quarterly analysis of 3 years shows Artiva Biotherapeutics' Depreciation & Amortization (CF) stood at $594,000 in 2023, then increased by 3.37% to $614,000 in 2024, then climbed by 5.58% to $662,000 in 2025.
  • Its Depreciation & Amortization (CF) was $662,000 in Q3 2025, compared to $641,000 in Q2 2025 and $628,000 in Q1 2025.